163 related articles for article (PubMed ID: 35672838)
1. Does the addition of whole-body MRI to routine imaging influence real-world treatment decisions in metastatic breast cancer?
Bhaludin BN; Tunariu N; Senthivel N; Babiker A; Soneji ND; Hujairi N; Sharma B; McGrath SE; Okines AF; Ring AE; Messiou C; Downey K; Koh DM
Cancer Imaging; 2022 Jun; 22(1):26. PubMed ID: 35672838
[TBL] [Abstract][Full Text] [Related]
2. A review on the added value of whole-body MRI in metastatic lobular breast cancer.
Bhaludin BN; Tunariu N; Koh DM; Messiou C; Okines AF; McGrath SE; Ring AE; Parton MM; Sharma B; Gagliardi T; Allen SD; Pope R; Johnston SRD; Downey K
Eur Radiol; 2022 Sep; 32(9):6514-6525. PubMed ID: 35384456
[TBL] [Abstract][Full Text] [Related]
3. The addition of whole-body magnetic resonance imaging to body computerised tomography alters treatment decisions in patients with metastatic breast cancer.
Kosmin M; Makris A; Joshi PV; Ah-See ML; Woolf D; Padhani AR
Eur J Cancer; 2017 May; 77():109-116. PubMed ID: 28390297
[TBL] [Abstract][Full Text] [Related]
4. The added value of whole-body magnetic resonance imaging in the management of patients with advanced breast cancer.
Zugni F; Ruju F; Pricolo P; Alessi S; Iorfida M; Colleoni MA; Bellomi M; Petralia G
PLoS One; 2018; 13(10):e0205251. PubMed ID: 30312335
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma.
Westerland O; Amlani A; Kelly-Morland C; Fraczek M; Bailey K; Gleeson M; El-Najjar I; Streetly M; Bassett P; Cook GJR; Goh V;
Eur J Nucl Med Mol Imaging; 2021 Jul; 48(8):2558-2565. PubMed ID: 33469686
[TBL] [Abstract][Full Text] [Related]
6. Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or
Gariani J; Westerland O; Natas S; Verma H; Cook G; Goh V
Crit Rev Oncol Hematol; 2018 Apr; 124():66-72. PubMed ID: 29548488
[TBL] [Abstract][Full Text] [Related]
7. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.
Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S
J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138
[TBL] [Abstract][Full Text] [Related]
8. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
9. Staging of neuroendocrine tumours: comparison of [⁶⁸Ga]DOTATOC multiphase PET/CT and whole-body MRI.
Schraml C; Schwenzer NF; Sperling O; Aschoff P; Lichy MP; Müller M; Brendle C; Werner MK; Claussen CD; Pfannenberg C
Cancer Imaging; 2013 Mar; 13(1):63-72. PubMed ID: 23466785
[TBL] [Abstract][Full Text] [Related]
10. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
11. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone.
Kosmin M; Padhani AR; Gogbashian A; Woolf D; Ah-See ML; Ostler P; Sutherland S; Miles D; Noble J; Koh DM; Marshall A; Dunn J; Makris A
Radiology; 2020 Dec; 297(3):622-629. PubMed ID: 33078998
[TBL] [Abstract][Full Text] [Related]
13. Whole Body MRI in the Staging of Esophageal Cancer--A Prospective Comparison with Whole Body 18F-FDG PET-CT.
Malik V; Harmon M; Johnston C; Fagan AJ; Claxton Z; Ravi N; O'Toole D; Muldoon C; Keogan M; Reynolds JV; Meaney JF
Dig Surg; 2015; 32(5):397-408. PubMed ID: 26315570
[TBL] [Abstract][Full Text] [Related]
14. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study.
Jouvet JC; Thomas L; Thomson V; Yanes M; Journe C; Morelec I; Bracoud L; Durupt F; Giammarile F; Berthezene Y
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):176-85. PubMed ID: 23331931
[TBL] [Abstract][Full Text] [Related]
15. Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru A; Young P; Mittra E; Dick DW; Herfkens R; Gambhir SS
Clin Nucl Med; 2013 Jul; 38(7):e290-6. PubMed ID: 23455520
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Bone Lesions with
van Es SC; Velleman T; Elias SG; Bensch F; Brouwers AH; Glaudemans AWJM; Kwee TC; Iersel MW; Maduro JH; Oosting SF; de Vries EGE; Schröder CP
J Nucl Med; 2021 Feb; 62(2):177-183. PubMed ID: 32817140
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
19. Head-to-Head Evaluation of
Ulaner GA; Jhaveri K; Chandarlapaty S; Hatzoglou V; Riedl CC; Lewis JS; Mauguen A
J Nucl Med; 2021 Mar; 62(3):326-331. PubMed ID: 32680923
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of 18F-FDG-PET/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer.
Al-Muqbel KM; Yaghan RJ
Medicine (Baltimore); 2016 May; 95(21):e3753. PubMed ID: 27227942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]